Business Wire

REPLY

28.4.2022 14:02:13 CEST | Business Wire | Press release

Share
REPLY: Area42, the Development Centre Dedicated to the Most Innovative Technologies in the Robotics, Advanced Mobility and Virtual Reality Sectors, Opens Its Doors

Today Reply inaugurates Area42 , the new applied research centre focused on developing the most innovative technologies. The Area42 “corner Labs” are driven by cutting-edge work in the areas of Autonomous Warehouse, Last Mile Delivery, Robotics, Connected Products, Blockchain and the Metaverse . Reply’s experts are working on these technologies on a daily basis, transforming ideas into innovative prototypes, exploiting their full potential and applying them to real use industrial cases.

The Area42 Laboratories are the distinctive component of Reply’s new Turin headquarters, which covers an area of over 20,000 square metres. Each workspace has been completely renovated and optimised in line with the Group’s new working models, which focus on a more open and collaborative approach. Reply will host its customers in the new spaces, collaborating with them to experiment, incubate new concepts, and test the latest technologies in a way that enables digital products and services to be adapted to their specific innovation context.

The 6 Area42 Laboratories focus on the key themes representing the most advanced frontiers of innovation for the industrial world:

- Autonomous Warehouse, the Area42 laboratory where solutions are studied and developed for the autonomous management of warehouse activities, thanks to the use of autonomous drones and vehicles capable of interfacing with innovative warehouse management platforms such as LEA Reply;

- Last mile delivery , the Area42 laboratory focused on the mobility of self-driving vehicles and robots within pre-defined spaces (e.g., campuses, hospitals, factories, etc.) that are capable of interacting with the surrounding environment;

- Robotics , the Area42 laboratory that combines Artificial Intelligence technologies with robotics to study the agility of autonomous robots and use scenarios focused on the interaction between the latter and large environments requiring repetitive maintenance and control activities;

- Connected Products, the Area42 space focused on the design and development of connected products and services, from the prototyping of devices to the creation of front-end applications, also thanks to the support of IoT accelerators;

- Blockchain , in the context of an ever-greater evolution of the concepts of smart cities and shared mobility, this Area42 laboratory experiments with the application of blockchain technologies for enabling real scenarios based on the Digital Identity of Vehicles;

- Metaverse, the Area42 laboratory focused on the application and integration of Mixed Reality solutions to create immersive applications in virtual environments, where users can enter and move around and where virtual and physical objects co-exist.

“The Area42 laboratories represent a unicum in the modern technological panorama,” affirmed Filippo Rizzante, Reply CTO. “Here, we give life to new and innovative concepts and apply the latest technologies to provide solutions capable of creating value for business and for society as a whole. We experiment with and implement innovative ideas that have a strategic impact and generate a competitive advantage for our customers. Currently, our focus is on six highly topical issues, but technological evolution will always continue to drive us further, in line with what has always been our approach at Reply: to prepare for and make the future a tangible reality”.

Area42 joins Reply’s existing laboratories in Europe: the Test Automation Centre , focused on the automated monitoring and testing of the quality of business-critical products and services; the IoT Validation Lab , where interconnected solutions are validated and also integrated with Reply’s new Turin headquarters, creating the most advanced hub of laboratories for the industry sector; Area 360, the centre for augmented and virtual reality based in Milan which was created to support businesses; the Immersive Experience Lab in Munich, which experiments with next-generation immersive experiences; the Cyber Security Lab , in Cologne, focused on the study and testing of cyber threats; and finally, Reply’s new labs opening soon in London which will be dedicated to robotics, edge computing and sensory technologies.

“The creation of Area42 is part of a broader project of excellence in terms of property redevelopment that we have initiated here in Turin”, continues Tatiana Rizzante. “While carefully respecting the constraints imposed by the Superintendency of Architectural Heritage in relation to what is certainly considered a symbol of modern architecture, we wanted to create harmonious and stimulating spaces to work, exchange ideas and carry out research. The interconnection of spaces created to accommodate different functions – from individual to team work, from the sharing of projects to leisure time, from lounges to the most advanced laboratories – creates a fluid and open space. Our team of experts, but also our customers and partners, can thus take advantage of a truly immersive experience and experiment with technological innovation”.

The Lingotto building that hosts Area42, located in Via Nizza no. 250 in Turin and recently acquired by the Group, has been the subject of a major renovation project which, together with works currently under way at the former Caserma de Sonnaz, make it possible to revive and reinterpret – with a contemporary touch – two iconic buildings for the city of Turin.

The projects are driven by the concepts of innovation, collaboration and well-being, placing the focus on the two main protagonists: people and research.

The completely renovated Lingotto building offers open spaces and new paths, created to facilitate business relationships and enlivened by the most current languages and codes. Reply’s people find themselves immersed in a large, multi-functional space with areas off limits to mobile phones and meetings to facilitate concentration. Common areas are dedicated not only to brainstorming, but also to sports, catering and leisure, for a more effective sharing of ideas and socialisation in the workplace: an active and ever-evolving ecosystem.

Reply

Reply [MTA, STAR: REY, ISIN: IT0005282865] specialises in the design and implementation of solutions based on new communication channels and digital media. As a network of highly specialised companies, Reply defines and develops business models enabled by the new models of AI, big data, cloud computing, digital media and the internet of things. Reply delivers consulting, system integration and digital services to organisations across the telecom and media; industry and services; banking and insurance; and public sectors. www.reply.com

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye